{"denoms":[{"counts":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"174"},{"groupId":"BG002","value":"347"}],"units":"Participants"}],"groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"BG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"BG001","title":"Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.1","value":"50.3"},{"groupId":"BG001","spread":"13.0","value":"49.8"},{"groupId":"BG002","spread":"13.0","value":"50.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"193"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"154"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gender","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis set (FAS) included all participants who were randomized to study treatment."}